Long‐term response to crizotinib in a 17‐year‐old boy with treatment‐naïve ALK‐positive non‐small‐cell lung cancer

BACKGROUND: Lung cancer is the leading cause of cancer‐related death. NSCLC accounts for 80–90% of cases. In young patients, adenocarcinoma is the most frequent histotype and 3–7% expresses the rearrangement of ALK oncogene, sensitive to TKIs. Crizotinib is the first ALK inhibitor approved by the FD...

Descripción completa

Detalles Bibliográficos
Autores principales: Megaro, Giacomina, Miele, Evelina, Spinelli, Gian Paolo, Alessi, Iside, Del Baldo, Giada, Cozza, Raffaele, Russo, Ida, De Pasquale, Maria Debora, Cefalo, Maria Giuseppina, Tomà, Paolo, Carai, Andrea, Di Ruscio, Valentina, De Ioris, Maria Antonietta, Mastronuzzi, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955048/
https://www.ncbi.nlm.nih.gov/pubmed/35092185
http://dx.doi.org/10.1002/cnr2.1483
Descripción
Sumario:BACKGROUND: Lung cancer is the leading cause of cancer‐related death. NSCLC accounts for 80–90% of cases. In young patients, adenocarcinoma is the most frequent histotype and 3–7% expresses the rearrangement of ALK oncogene, sensitive to TKIs. Crizotinib is the first ALK inhibitor approved by the FDA. CASE: We present a case of a 17‐year‐old male with metastatic treatment‐naïve ALK‐positive adenocarcinoma. He was treated with crizotinib and obtained a prolonged response with PFS of 33 months. CONCLUSION: Crizotinib can be extremely effective in adolescents with treatment‐naïve ALK‐positive NSCLC but fail to prevent a central nervous system relapse. Resistance mechanisms need to be investigated.

Ejemplares similares